PepGen Inc. (NASDAQ: PEPG) announced on September 25, 2025, that its Phase 1 clinical trial for Type 1 myotonic dystrophy, FREEDOM-DM1, achieved unprecedented results, with the stock price rising by more than 114%. The trial results showed that under the treatment of PGN-EDODM1 at a dose of 15 mg/kg, the average splicing correction rate was 53.7%, significantly higher than any previously reported results. All patients in the highest dose group responded well, and no serious adverse events occurred. The company also publicly issued 31,250,000 shares at a price of $3.20 per share, raising $100 million to support the further development of its DM1 project.